Abstract:AbstractCytosolic DNA sensing is an important process during the innate immune response that activates the stimulator of interferon genes (STING) adaptor and induces IFN-I. STING incites spontaneous immunity during immunogenic tumor growth and accordingly, STING agonists induce regression of therapy-resistant tumors. However DNA, STING agonists, and apoptotic cells can also promote tolerogenic responses via STING by activating immunoregulatory mechanisms such as indoleamine 2,3 dioxygenase (IDO). Here, we show that IDO activity induced by STING activity in the tumor microenvironment (TME) promoted the growth of Lewis lung carcinoma (LLC). Although STING also induced IDO in tumor-draining lymph nodes (TDLN) during EL4 thymoma growth, this event was insufficient to promote tumorigenesis. In the LLC model, STING ablation enhanced CD8+ T-cell infiltration and tumor cell killing while decreasing myeloid-derived suppressor cell infiltration and IL10 production in the TME. Depletion of CD8+ T cells also eliminated the growth disadvantage of LLC tumors in STING-deficient mice, indicating that STING signaling attenuated CD8+ T-cell effector functions during tumorigenesis. In contrast with native LLC tumors, STING signaling neither promoted growth of neoantigen-expressing LLC, nor did it induce IDO in TDLN. Similarly, STING failed to promote growth of B16 melanoma or to induce IDO activity in TDLN in this setting. Thus, our results show how STING-dependent DNA sensing can enhance tolerogenic states in tumors characterized by low antigenicity and how IDO inhibition can overcome this state by attenuating tumor tolerance. Furthermore, our results reveal a greater complexity in the role of STING signaling in cancer, underscoring how innate immune pathways in the TME modify tumorigenesis in distinct tumor settings, with implications for designing effective immunotherapy trials. Cancer Res; 76(8); 2076–81. ©2016 AACR.

STING-mediated DNA sensing in cancer immunotherapy

Activation of Stimulation of Interferon Genes (STING) Signal and Cancer Immunotherapy

Cell-to-cell communications of cGAS-STING pathway in tumor immune microenvironment.

Chemical Biology Perspectives on STING Agonists as Tumor Immunotherapy

Targeting STING signaling for the optimal cancer immunotherapy

Structural Insights into a Shared Mechanism of Human STING Activation by a Potent Agonist and an Autoimmune Disease-Associated Mutation.

Strategies involving STING pathway activation for cancer immunotherapy: mechanism and agonists

Synthetic Enforcement of STING Signaling in Cancer Cells Appropriates the Immune Microenvironment for Checkpoint Inhibitor Therapy.

The cGAS/STING Pathway: A Novel Target for Cancer Therapy

Advances in the Prerequisite and Consequence of STING Downstream Signalosomes

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.

The multiple faces of cGAS-STING in antitumor immunity: prospects and challenges

cGAS-STING pathway mediates activation of dendritic cell sensing of immunogenic tumors

Emerging mechanisms and implications of cGAS-STING signaling in cancer immunotherapy strategies

Immune Regulation of the cGAS-STING Signaling Pathway in the Tumor Microenvironment and Its Clinical Application

Novel Emerging Nano-Assisted Anti-Cancer Strategies Based on the STING Pathway

GAS-STING: a classical DNA recognition pathways to tumor therapy

Clinical applications of STING agonists in cancer immunotherapy: current progress and future prospects

cGAS-STING pathway in cancer biotherapy

STING pathway as a cancer immunotherapy: Progress and challenges in activating anti-tumor immunity

STING Promotes the Growth of Tumors Characterized by Low Antigenicity Via IDO Activation.